Targeted light therapy with chemotherapy for newly diagnosed butterfly glioblastoma
Treatments studied
Part of Cancer clinical trials.
This trial tests a new light-based treatment that is given alongside standard chemotherapy and radiation for people with a type of brain tumor called 'butterfly glioblastoma'. The goal is to see if adding this therapy can improve outcomes for patients with this challenging condition.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 80 years old.
- You have a newly diagnosed glioblastoma that involves both sides of the brain (butterfly pattern) and is confirmed by biopsy.
- Your overall health is good enough to perform daily activities (WHO performance status 0-2).
- Your blood counts and major organ function (liver and kidneys) are within acceptable ranges.
- You are not pregnant, are willing to use contraception, and agree to avoid certain medications that can cause light sensitivity.
- Your head size and any prior surgical openings are within specified limits to fit the treatment helmet.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new approach that uses a light-sensitive drug and low-intensity ultrasound to make standard chemotherapy more effective for glioblastoma. If you have completed initial treatment with radiation and temozolomide without the tumor growing, you may be eligible.
This study tests a light-activated therapy (radiodynamic therapy) using a special medicine to help treat a brain tumor that has come back after prior treatment. It may be offered after doctors decide you need further radiation for your recurrence.
This trial tests combining an immunotherapy drug (adebrelimab) with the standard chemotherapy temozolomide, with or without hyperbaric oxygen treatment, for patients with newly diagnosed glioblastoma who have already completed standard radiation and chemotherapy. The goal is to see if this combination can improve outcomes.
This trial tests whether adding an experimental drug called liposomal transcrocetin (L-TC) to the standard treatment of radiation and temozolomide chemotherapy helps people with newly diagnosed glioblastoma. It aims to see if the combination improves outcomes compared to standard care alone.
This early-phase study tests whether liposomal curcumin, added to standard radiation plus temozolomide, can improve treatment outcomes in newly diagnosed high-grade gliomas. It focuses on safety and how well the treatment can be given with the usual therapy plan.
This study tests a new medicine (MT-125) combined with standard radiation and chemotherapy for people with newly diagnosed glioblastoma that has a specific gene change (MGMT methylated). The goal is to see if it is safe and tolerable, and to look for early signs it might help.
Hear when a new Glioblastom WHO Grade 4 trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.